Nov 23, 2019: Data updated by Takeda Pharmaceutical from its Phase 3 ALTA-1L trial evaluating ALUNBRIG versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not been received a prior ALK inhibitor.
After two years, ALUNBRIG reduced the risk of disease progression or death by 76% as appraised by investigators in newly diagnosed patients whose disease have spread to the brain at time of registration.
Study investigators and a blinded independent review committee (BIRC) evaluates the ALTA-1L trial and results from both assessments were reported, the BIRC-assessed HR of progression-free survival (PFS), which is the primary endpoint, was 95% whereas demonstrating a reduced risk of disease progression or death by 51%.
Study showed that as compared with the ALTA study in a post-crizotinib population, the frequency of early pulmonary events (interstitial lung disease/pneumonitis) in the ALTA-1L trial was somewhat lower. https://www.takeda.com/newsroom/newsreleases/2019/takeda-presents-long-term-data-in-alk-nsclc-showing-alunbrig-brigatinib-continues-to-demonstrate-superiority-in-the-first-line-after-two-years-of-follow-up/